BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Annese T, Tamma R, Ribatti D. Update in TIGIT Immune-Checkpoint Role in Cancer. Front Oncol 2022;12:871085. [PMID: 35656508 DOI: 10.3389/fonc.2022.871085] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Secchiari F, Nuñez SY, Sierra JM, Ziblat A, Regge MV, Raffo Iraolagoitia XL, Rovegno A, Ameri C, Secin FP, Richards N, Ríos Pita H, Vitagliano G, Rico L, Mieggi M, Frascheri F, Bonanno N, Blas L, Trotta A, Friedrich AD, Fuertes MB, Domaica CI, Zwirner NW. The MICA-NKG2D axis in clear cell renal cell carcinoma bolsters MICA as target in immuno-oncology. OncoImmunology 2022;11:2104991. [DOI: 10.1080/2162402x.2022.2104991] [Reference Citation Analysis]
2 Perez-santos M, Anaya-ruiz M, Villafaña-diaz L, Sánchez Esgua G. Approaches for development of LAG-3 inhibitors and the promise they hold as anticancer agents. Expert Opinion on Drug Discovery 2022. [DOI: 10.1080/17460441.2022.2148652] [Reference Citation Analysis]
3 Munari E, Quatrini L, Ciancaglini C, Eccher A, Bogina G, Moretta L, Mariotti FR. Immunotherapy targeting inhibitory checkpoints: The role of NK and other innate lymphoid cells. Seminars in Immunology 2022;61-64:101660. [DOI: 10.1016/j.smim.2022.101660] [Reference Citation Analysis]
4 Xie Y, Kong W, Zhao X, Zhang H, Luo D, Chen S. Immune checkpoint inhibitors in cervical cancer: Current status and research progress. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.984896] [Reference Citation Analysis]
5 Mizuno T, Katsuya Y, Sato J, Koyama T, Shimizu T, Yamamoto N. Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China. Front Oncol 2022;12:925938. [DOI: 10.3389/fonc.2022.925938] [Reference Citation Analysis]